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Editorial page 225
IMPORTANCE Despite improvement during recent decades, extremely preterm infants

Supplemental content

continue to contribute disproportionately to neonatal mortality and childhood morbidity.
OBJECTIVE To review survival, in-hospital morbidities, care practices, and neurodevelopmental

and functional outcomes at 22-26 months’ corrected age for extremely preterm infants.
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DESIGN, SETTING, AND PARTICIPANTS Prospective registry for extremely preterm infants born
at 19 US academic centers that are part of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development Neonatal Research Network. The study included
10 877 infants born at 22-28 weeks’ gestational age between January 1, 2013, and December
31, 2018, including 2566 infants born before 27 weeks between January 1, 2013, and
December 31, 2016, who completed follow-up assessments at 22-26 months’ corrected age.
The last assessment was completed on August 13, 2019. Outcomes were compared with
a similar cohort of infants born in 2008-2012 adjusting for gestational age.
EXPOSURES Extremely preterm birth.
MAIN OUTCOMES AND MEASURES Survival and 12 in-hospital morbidities were assessed,
including necrotizing enterocolitis, infection, intracranial hemorrhage, retinopathy of
prematurity, and bronchopulmonary dysplasia. Infants were assessed at 22-26 months’
corrected age for 12 health and functional outcomes, including neurodevelopment, cerebral
palsy, vision, hearing, rehospitalizations, and need for assistive devices.
RESULTS The 10 877 infants were 49.0% female and 51.0% male; 78.3% (8495/10848) survived
to discharge, an increase from 76.0% in 2008-2012 (adjusted difference, 2.0%; 95% CI,
1.0%-2.9%). Survival to discharge was 10.9% (60/549) for live-born infants at 22 weeks and
94.0% (2267/2412) at 28 weeks. Survival among actively treated infants was 30.0% (60/200) at
22 weeks and 55.8% (535/958) at 23 weeks. All in-hospital morbidities were more likely among
infants born at earlier gestational ages. Overall, 8.9% (890/9956) of infants had necrotizing
enterocolitis, 2.4% (238/9957) had early-onset infection, 19.9% (1911/9610) had late-onset
infection, 14.3% (1386/9705) had severe intracranial hemorrhage, 12.8% (1099/8585) had
severe retinopathy of prematurity, and 8.0% (666/8305) had severe bronchopulmonary
dysplasia. Among 2930 surviving infants with gestational ages of 22-26 weeks eligible for
follow-up, 2566 (87.6%) were examined. By 2-year follow-up, 8.4% (214/2555) of children had
moderate to severe cerebral palsy, 1.5% (38/2555) had bilateral blindness, 2.5% (64/2527)
required hearing aids or cochlear implants, 49.9% (1277/2561) had been rehospitalized, and
15.4% (393/2560) required mobility aids or other supportive devices. Among 2458 fully
evaluated infants, 48.7% (1198/2458) had no or mild neurodevelopmental impairment at
follow-up, 29.3% (709/2419) had moderate neurodevelopmental impairment, and 21.2%
(512/2419) had severe neurodevelopmental impairment.
CONCLUSIONS AND RELEVANCE Among extremely preterm infants born in 2013-2018 and
treated at 19 US academic medical centers, 78.3% survived to discharge, a significantly higher
rate than for infants born in 2008-2012. Among infants born at less than 27 weeks’
gestational age, rehospitalization and neurodevelopmental impairment were common
at 2 years of age.
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M

ortality and most short-term morbidities among extremely preterm infants have declined in recent
decades,1-5 but ongoing review of medical and neurodevelopmental outcomes is needed as care strategies and
technologies continue to evolve. Published reports of trends
in neurodevelopmental outcomes among extremely preterm
infants who survive differ, highlighting challenges to interpretation due to variation in age at assessment, assessment instruments, and other factors.6-10 Moreover, additional postdischarge milestones including functional and healthrelated outcomes are increasingly recognized as important for
children born extremely preterm and their families.10-14
The Eunice Kennedy Shriver National Institute of Child
Health and Human Development Neonatal Research Network tracks in-hospital outcomes for infants born before 29
weeks’ gestational age at network centers. At 22-26 months’
corrected age,15 the neurological and developmental status of
those born before 27 weeks are assessed by certified examiners. Since 1991, the network has periodically reported extremely preterm infant in-hospital mortality and morbidity outcomes and longer-term developmental outcomes. Network
investigators have not previously published a comprehensive update on both short-term and postdischarge follow-up
outcomes. This study was conducted to assess mortality, inhospital morbidities, and care practices for infants born in 20132018 and neurodevelopmental, functional, and healthrelated outcomes at 22-26 months’ corrected age for infants
born in 2013-2016.

Methods
The Neonatal Research Network’s extremely preterm infant
registry enrolls infants born weighing 401 g to 1000 g and/or
born between 22 weeks 0 days’ and 28 weeks 6 days’ gestation at network hospitals. Trained research coordinators
prospectively collect maternal and neonatal data from birth
until discharge home, transfer, death, or 120 days. For
infants transferred or still hospitalized at 120 days, vital status is collected until 1 year of age. Surviving infants born
before 27 weeks are eligible for comprehensive follow-up
assessment at 22-26 months’ corrected age. The institutional review board at each participating hospital approved
participation in the registry. Waiver of consent for enrollment in the extremely preterm infant registry was granted
at most affiliated hospitals, but parental consent was
required at 5 hospitals (4 written, 1 oral). Most hospitals
required written parental consent for participation in the
follow-up study, but 5 hospitals allowed participation under
waiver of consent.
Infants born at each of 19 network centers between January 1, 2013, and December 31, 2018, at gestational ages of
22-28 weeks and enrolled in the registry were included in the
present study. Postdischarge outcomes assessed at the 2-year
follow-up visit were available for infants born between January 1, 2013, and December 31, 2016. The final in-hospital outcome was determined on December 20, 2019; the final 2-year
assessment was completed on August 13, 2019.

Original Investigation Research

Key Points
Question Among extremely preterm infants born at US academic
medical centers between 2013 and 2018, what were mortality,
in-hospital morbidity, and 2-year neurodevelopmental outcomes?
Findings In this observational study based on a prospective
registry of 10 877 infants born at 22-28 weeks’ gestational age in
2013-2018 in 19 US academic medical centers, survival to
discharge occurred in 78.3% and was significantly improved
compared with a historical rate of 76.0% among infants born in
2008-2012. Among infants born at less than 27 weeks’ gestational
age who survived to follow-up assessment at 2 years, 49.9% had
been rehospitalized and severe neurodevelopmental impairment
occurred in 21.2%.
Meaning Among extremely preterm infants born at US academic
medical centers from 2013 to 2018, survival to discharge
significantly improved compared with infants born in 2008-2012,
but among those born at less than 27 weeks’ gestational age,
rehospitalization and neurodevelopmental impairment at 2 years
were common.

Maternal demographic, pregnancy, and delivery information and infant characteristics were recorded. Gestational age
was determined by best obstetric estimate or, if unavailable,
by neonatal estimate. Maternal race and ethnicity were selfidentified from a list of options; race and ethnicity were included because they are known to be associated with differences in care and outcomes in preterm infants.16 Infants with
birth weights below the 10th percentile for gestational age17
were classified as small for gestational age. Clinical interventions and morbidities during the birth hospitalization were recorded for infants surviving longer than 12 hours.

Outcomes
Infant survival was recorded to 12 hours and to discharge or
1 year if still hospitalized. Morbidities recorded included necrotizing enterocolitis (modified Bell stage ≥IIA18,19), earlyonset sepsis and/or meningitis (≤72 hours), late-onset sepsis
and/or meningitis (>72 hours), intracranial hemorrhage
(grade III or IV20), cystic periventricular leukomalacia, retinopathy of prematurity, and bronchopulmonary dysplasia.
Bronchopulmonary dysplasia was defined using the optimal
definition (definition 15) from Jensen et al.21 This definition
classifies bronchopulmonary dysplasia based on the mode of
support received at 36 weeks’ postmenstrual age or at discharge home if earlier: no bronchopulmonary dysplasia is
classified as no support or breathing room air; grade 1, nasal
cannula at a flow rate of 2 L/min or lower; grade 2, nasal cannula at a flow rate higher than 2 L/min or noninvasive positive airway pressure; and grade 3, invasive mechanical ventilation. Active treatment was defined as intubation, surfactant
therapy, respiratory support, chest compressions, epinephrine, volume resuscitation, blood pressure support, and/or
parenteral nutrition.22
The 2-year study visit included structured interviews with
children’s primary caretakers to review medical history, rehospitalizations, and medical equipment use. A standardized neurologic examination and the Bayley Scales of Infant
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and Toddler Development, Third Edition (Bayley-III)23 were
administered by certified examiners who completed annual
training to ensure interrater reliability.24 Bayley-III cognitive,
language, and motor composite scores are normalized to a
mean of 100 (SD, 15), with lower scores indicating a higher degree of impairment. Severity of motor impairment was determined by the Gross Motor Function Classification System
(GMFCS) of Palisano et al.25 Mild cerebral palsy was defined
as GMFCS level 1, moderate as GMFCS level 2 or 3, and severe
as GMFCS level 4 or 5.
Mild or no neurodevelopmental impairment (NDI) was defined as a Bayley-III cognitive composite score of 85 or higher,
a Bayley-III motor composite score of 85 or higher, and GMFCS
level 0 or 1. Moderate NDI was defined as a Bayley-III cognitive composite score or motor composite score of 70 to 84 or
GMFCS level 2 or 3. Severe NDI was defined as a Bayley-III cognitive composite score or motor composite score lower than
70, GMFCS level 4 or 5, bilateral blindness, or bilateral severe
functional hearing impairment.6,8
The following outcomes were determined at the 2-year assessment by history from caregivers and/or medical records:
rehospitalization after initial discharge and reason for hospitalization; feeding assistance required; need for supportive
medical equipment, such as apnea monitor, oxygen, or other
respiratory support; and need for mobility aid, such as braces,
walker, or adaptive stroller or wheelchair.

Statistical Analysis
Descriptive statistics were used to summarize maternal characteristics, neonatal characteristics at birth, and survival for
all infants; in-hospital treatments and morbidities for infants
surviving more than 12 hours; and outcomes at follow-up
for infants evaluated. Survival was analyzed separately for
actively treated infants. Follow-up outcomes were included if
infants underwent neurologic examination and/or Bayley-III
assessment at 18-30 months’ corrected age, allowing for
4 months outside the targeted age.
Regression models were used to assess whether outcomes differed across gestational ages; reported P values
were adjusted for the covariates listed below. Logistic, generalized logit, and linear models were used to assess whether
binary proportions, categorical outcomes with more than 2
levels, or means differed by gestational age, with statistical
significance determined by Wald χ 2 or F tests. Quantile
regression was used to examine differences in medians
across gestational ages for outcomes with highly skewed distributions, with statistical significance determined by a likelihood ratio χ2 test. Models assessing survival, morbidities,
and treatments included gestational age, study center, small
for gestational age, sex, multiple gestation, and maternal race
and ethnicity. Covariates known to affect outcomes were
chosen a priori and entered in models simultaneously. Study
center was entered as a fixed effect in all models. Because of
the role of socioeconomic factors in postdischarge child
development, maternal education was added to models
examining outcomes at follow-up and was entered with a
category for missing/unknown data to minimize loss of
observations from the models. Each other covariate was
250

missing for less than 1% of the cohort. In total, less than 2%
of observations were excluded from most models (maximum
of 6% from 2 models) due to missing covariates or outcomes.
Unless otherwise indicated, reported P values indicate
whether there were differences in outcomes by gestational
age overall with all gestational age group comparisons considered together. Tests of overall differences by gestational
age are reported in the text and in table footnotes. Comparisons between 2 proportions at different gestational ages were
reported as risk (prevalence) differences with 95% MiettinenNurminen confidence intervals and P values by χ 2 test
indicating statistical significance for the pairwise comparison. P values, all 2-sided, were adjusted as described above.
A P < .05 was considered significant. Analyses were performed using SAS version 9.4 (SAS Institute Inc). Because of
the potential for type I error due to multiple comparisons, findings for the analyses should be interpreted as exploratory.
Percentages in the current cohort were compared with
percentages reported by Stoll et al1 for births at 22-28 weeks’
gestational age in Neonatal Research Network centers during
2008-2012, when outcomes were reported for the earlier
cohort. Risk differences adjusted for gestational age and 95%
confidence intervals were estimated for overall proportions
using binomial models. 26 Differences in proportions for
infants in 1 gestational age group were unadjusted. The outcome definitions were the same in the 2 studies with 2 exceptions. First, in the current study, no assumption was made
when an infant’s final vital status was unknown, while in the
study by Stoll et al,1 these infants were assumed to have survived to discharge (44 infants [0.5%]). Second, early- and
late-onset sepsis and/or meningitis included sepsis and/or
meningitis in the current cohort, but the reported proportions in the cohort of Stoll et al1 did not include meningitis;
this difference had minimal impact because few infants had
meningitis alone.

Results
Study Population
We studied 10 877 infants born between January 1, 2013, and
December 31, 2018, at Neonatal Research Network study centers with gestational ages of 22-28 weeks. The median maternal age was 29 (IQR, 24-33) years; 26.5% (n = 2886) of infants
were multiples, 49.0% (n = 5327) were female and 51.0%
(n = 5550) were male, 9.3% (n = 1016) were small for gestational age, and 5.5% (603/10 868) had major birth defects
(Table 1). Overall, 88.1% (9571/10 867) of mothers received corticosteroids, 75.0% (8135/10 847) received antibiotics, and
79.4% (8622/10 858) received magnesium sulfate. Although
64.8% (7043/10 867) of infants were born by cesarean delivery overall, only 3.1% (17/549) of infants at 22 weeks and 39.7%
(430/1083) at 23 weeks were born by cesarean delivery.

Survival
Overall, 9966 (91.6%) infants survived more than 12 hours and
8495 of 10 848 (78.3%) survived to discharge or to 1 year if still
hospitalized (Table 2; eFigure 1 in Supplement 1). Survival to
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Characteristicsa

99/376 (26.3)

100/376 (26.6) 236/859 (27.5)

Trade or technical school
or some college

College degree or more

7/522 (1.3)

233/522 (44.6) 530/1048 (50.6)

7/522 (1.3)

Native Hawaiian
or Other Pacific Islander

White

>1 Race
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526/1931 (27.2)

509/1931 (26.4)

557/1931 (28.8)

339/1931 (17.6)

29 (24-33)

28 (n = 2419)

2225/8667 (25.7)

2403/8667 (27.7)

2529/8667 (29.2)

1510/8667 (17.4)

29 (24-33)

22-28 (n = 10 877)

7/2354 (0.3)

870/2354 (37.0)

113/2354 (4.8)

37/2354 (1.6)

381/2395 (15.9)

46/10 555 (0.4)

4205/10 555 (39.8)

438/10 555 (4.1)

125/10 555 (1.2)

1733/10 776 (16.1)

27/2354 (1.1)

144/10 555 (1.4)

© 2022 American Medical Association. All rights reserved.
430/1083 (39.7)

17/549 (3.1)

912/1394 (65.4)

1096/1601 (68.5) 1356/1836 (73.9) 1438/1986 (72.4) 1794/2418 (74.2) 7043/10 867 (64.8)

1141/1396 (81.7) 1301/1602 (81.2) 1555/1832 (84.9) 1697/1985 (85.5) 2030/2414 (84.1) 8622/10 858 (79.4)

Cesarean delivery

510/10 762 (4.7)

1436/10 744 (13.4)

1503/10 744 (14.0)

137/548 (25.0) 761/1081 (70.4)

129/2388 (5.4)

486/2388 (20.4)

351/2388 (14.7)

1593/10 861 (14.7)

2886 (26.5)

Magnesium sulfate

116/1964 (5.9)

333/1962 (17.0)

344/1962 (17.5)

219/2415 (9.1)

659 (27.2)

1105/1394 (79.3) 1233/1601 (77.0) 1389/1833 (75.8) 1517/1981 (76.6) 1801/2412 (74.7) 8135/10 847 (75.0)

84/1818 (4.6)

257/1807 (14.2)

266/1807 (14.7)

230/1986 (11.6)

513 (25.8)

1266/1398 (90.6) 1448/1601 (90.4) 1699/1834 (92.6) 1851/1986 (93.2) 2253/2417 (93.2) 9571/10 867 (88.1)

69/1588 (4.3)

191/1583 (12.1)

227/1583 (14.3)

251/1831 (13.7)

509 (27.7)

282/548 (51.5) 808/1078 (75.0)

59/1385 (4.3)

112/1382 (8.1)

177/1382 (12.8)

263/1602 (16.4)

369 (23.0)

Antenatal antibiotics

35/1077 (3.2)

42/1077 (3.9)

104/1077 (9.7)

257/1396 (18.4)

326 (23.3)

Antenatal corticosteroids 177/548 (32.3) 877/1083 (81.0)

18/542 (3.3)

15/545 (2.8)

During but not before
pregnancy

Insulin-dependent
diabetes

34/545 (6.2)

Existing before
pregnancy

Hypertension

329 (30.4)

5548/8871 (62.5)

6249/8819 (70.9)

7506/8858 (84.7)

443/8836 (5.0)

2311 (26.0)

127/549 (23.1) 246/1082 (22.7)

20/1941 (1.0)

1044/1941 (53.8) 1300/2354 (55.2) 5597/10 555 (53.0)

11/1941 (0.6)

744/1941 (38.3)

92/1941 (4.7)

30/1941 (1.5)

297/1971 (15.1)

Chorioamnionitis
documented
in medical record

31/1777 (1.7)

961/1777 (54.1)

9/1777 (0.5)

689/1777 (38.8)

66/1777 (3.7)

21/1777 (1.2)

311/1821 (17.1)

181 (32.9)

22/1549 (1.4)

850/1549 (54.9)

4/1549 (0.3)

410/1580 (25.9)

459/1580 (29.1)

443/1580 (28.0)

268/1580 (17.0)

29 (24-33)

27 (n = 1987)

1064/1830 (58.1) 1121/1978 (56.7) 1393/2417 (57.6) 6192/10 842 (57.1)

368/1514 (24.3)

440/1514 (29.1)

433/1514 (28.6)

273/1514 (18.0)

29 (24-33)

26 (n = 1836)

516/547 (94.3) 1034/1081 (95.7) 1326/1394 (95.1) 1522/1599 (95.2) 1759/1832 (96.0) 1918/1984 (96.7) 2323/2410 (96.4) 10398/10 847 (95.9) 8444/8834 (95.6)

21/1364 (1.5)

679/1364 (49.8)

6/1364 (0.4)

602/1549 (38.9)

59/1549 (3.8)

12/1549 (0.8)

267/1585 (16.8)

894/1598 (55.9)

329/1272 (25.9)

345/1272 (27.1)

363/1272 (28.5)

235/1272 (18.5)

29 (24-33)

25 (n = 1604)

Multiple gestation

16/1048 (1.5)

2/1048 (0.2)

594/1364 (43.5)

50/1364 (3.7)

14/1364 (1.0)

228/1390 (16.4)

814/1394 (58.4)

256/1135 (22.6)

309/1135 (27.2)

379/1135 (33.4)

191/1135 (16.8)

28 (24-33)

24 (n = 1398)

(continued)

2.4 (1.2 to 3.7)

4.5 (3.2 to 5.7)

3.3 (2.5 to 4.2)

−0.1 (−0.7 to 0.5)

0.3 (−0.9 to 1.5)

0.3 (−0.3 to 0.9)

Gestational age, wk,
Adjusted
2008-2012b
difference
(95% CI)c
22-28 (n = 8877)

Prenatal care (≥1 visit)

f

Characteristics of pregnancy
and delivery, No./total (%)

251/522 (48.1) 455/1048 (43.4)

Black

39/1048 (3.7)

19/522 (3.6)

Asian

6/1048 (0.6)

5/522 (1.0)

American Indian
or Alaska Native

Race, No./total (%)

169/1070 (15.8)

312/547 (57.0) 594/1078 (55.1)

Hispanic or Latino ethnicity, 80/544 (14.7)
No./total (%)

Public medical insurancee

116/376 (30.9) 238/859 (27.7)
242/859 (28.2)

61/376 (16.2)

143/859 (16.6)

28 (23-32)

23 (n = 1083)

High school diploma

28 (23-32)

22 (n = 550)

Less than high school

Education, No./total (%)d

Age, median (IQR), y

Maternal characteristics

Gestational age, wk, 2013-2018

Table 1. Maternal and Infant Characteristics and Antenatal Therapies for Infants Born at 22-28 Weeks’ Gestational Age
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533 (49.2)

21/550 (3.8)

201 (36.5)

Major birth defect,
No. (%)h

Actively treated at birth,
No. (%)i
1369 (97.9)

63/1396 (4.5)

110 (7.9)

660 (585-730)

727 (52.0)

671 (48.0)

24 (n = 1398)

1589 (99.1)

109/1603 (6.8)

170 (10.6)

760 (660-843)

804 (50.1)

800 (49.9)

25 (n = 1604)

Data are from Stoll et al. Infants included were restricted to those with birth weights of 401 g to 1500 g,
consistent with Neonatal Research Network eligibility criteria during prior years. This criterion primarily
restricted eligibility for infants born at 22 weeks’ gestational age. The current cohort includes infants born at
22-28 weeks’ gestational age with any birth weight, including 163 (1.5%) with birth weights less than 401 g and
79 (0.7%) with birth weights greater than 1500 g.

Where possible given data reported by Stoll et al, differences adjusted for gestational age are shown between
the proportion reported for infants born at 22-28 weeks’ gestational age in the 2013-2018 cohort vs in
2008-2012 along with associated 95% confidence intervals for the difference. A positive difference indicates
that the proportion increased in the 2013-2018 cohort compared with the 2008-2012 cohort; a negative
difference indicates that the proportion decreased in the 2013-2018 cohort compared with the earlier cohort.

c

1

5550 (51.0)

5327 (49.0)

22-28 (n = 10 877)

Antenatal corticosteroid use was defined as any antenatal corticosteroid given. Of the 9571 infants who received
antenatal corticosteroids, information about whether a complete course was given was missing for 23 infants.
Of the remaining 9548 infants, 7203 (75.4%) received a complete course and 2345 (24.6%) did not.
Small for gestational age was defined as less than the 10th percentile for sex and age based on Alexander
percentiles.17
Major birth defect refers to any syndrome and/or major malformation including chromosomal abnormalities,
central nervous system defects, congenital heart defects, gastrointestinal tract defects, genitourinary tract
defects, skeletal dysplasias, cystic adenomatoid malformation, inborn errors of metabolism, and other serious
or life-threatening birth defects.
Active treatment was defined as intubation, surfactant therapy, respiratory support, chest compressions,
epinephrine, volume resuscitation, blood pressure support, or parenteral nutrition.22

g

h

i

1.8 (1.2 to 2.4)

2.4 (1.6 to 3.2)

f

331/8876 (3.7)

656/8873 (7.4)

−0.9 (−2.3 to 0.5)

Public medical insurance may include Medicaid, a state or federally funded program, or insurance obtained
through the Affordable Care Act.

10320 (94.9)

603/10 868 (5.5)

1016 (9.3)

4273/8873 (48.2)
4600/8873 (51.8)

Maternal education was assessed at the time of delivery.

2400 (99.2)

158/2416 (6.5)

259 (10.7)

1103 (950-1240) 810 (640-1014)

1212 (50.1)

1207 (49.9)

28 (n = 2419)

e

1976 (99.4)

101/1985 (5.1)

193 (9.7)

970 (840-1090)

1003 (50.5)

984 (49.5)

27 (n = 1987)

Gestational age, wk,
Adjusted
2008-2012b
difference
(95% CI)c
22-28 (n = 8877)

d

1827 (99.5)

109/1835 (5.9)

184 (10.0)

860 (745-965)

967 (52.7)

869 (47.3)

26 (n = 1836)

Characteristic distributions differed significantly across gestational age for maternal age, maternal race, multiple
gestation, chorioamnionitis, hypertension existing before pregnancy, hypertension during but not before
pregnancy, insulin-dependent diabetes, antenatal corticosteroids, antenatal antibiotics, magnesium sulfate,
cesarean delivery, infant birth weight, small for gestational age, presence of birth defect, and active treatment at
birth; adjusted P < .01 for all except P = .02 for insulin-dependent diabetes, adjusting for study center.

958 (88.5)

42/1083 (3.9)

62 (5.7)

38 (6.9)

Small for gestational age,
No. (%)g

550 (50.8)

480 (431-528) 575 (520-637)

Male

23 (n = 1083)

Birth weight,
median (IQR), g

263 (47.8)

287 (52.2)

Female

Sex, No. (%)

22 (n = 550)

b

a

Characteristicsa

Infant characteristics

Gestational age, wk, 2013-2018

Table 1. Maternal and Infant Characteristics and Antenatal Therapies for Infants Born at 22-28 Weeks’ Gestational Age (continued)
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Survival

56/549 (10.2)

4/549 (0.7)

Discharged home

Remained in hospital
at 1 y

535/958 (55.8)

159 (79.1)

60/200 (30.0)

56/200 (28.0)

4/200 (2.0)

Survived to discharge
or 1 yc

Discharged home

Remained in hospital
at 1 y

25

26

27

28

22-28

Where possible given data reported by Stoll et al, differences adjusted for gestational age are shown between
the proportion reported for infants born at 22-28 weeks’ gestational age in the 2013-2018 cohort vs in
2008-2012 along with associated 95% confidence intervals for the difference. A positive difference indicates
that the proportion increased in the 2013-2018 cohort compared with the 2008-2012 cohort; a negative
difference indicates that the proportion decreased in the 2013-2018 cohort compared with the earlier cohort.

For infants who transferred or were still hospitalized at 120 days, vital status was collected up to 1 year.

c

d

15/1968 (0.8)

1772/1968 (90.0)

1787/1968 (90.8)

1943 (98.3)

1976

15/1979 (0.8)

1772/1979 (89.5)

1787/1979 (90.3)

1943 (97.8)

1987

8/2393 (0.3)

2258/2393 (94.4)

2266/2393 (94.7)

2375 (99.0)

2400

8/2412 (0.3)

2259/2412 (93.7)

2267/2412 (94.0)

2376 (98.2)

2419

113/10 291 (1.1)

8381/10 291 (81.4)

8494/10 291 (82.5)

9965 (96.6)

10 320

113/10 848 (1.0)

8382/10 848 (77.3)

8495/10 848 (78.3)

9966 (91.6)

10 877

6746/8877 (76.0)

8034 (90.5)

8877

2.0 (1.0 to 2.9)

0.1 (−0.3 to 0.6)

Adjusted
difference
(95% CI)b

jama.com
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Active treatment was defined as intubation, surfactant therapy, respiratory support, chest compressions,
epinephrine, volume resuscitation, blood pressure support, or parenteral nutrition.22

The proportion of infants who survived more than 12 hours and the proportion who survived to discharge or
1 year differed significantly across gestational age; adjusted P < .001 for each by Wald χ2 test adjusting for study
center, small for gestational age, male sex, multiple gestation, and maternal race and ethnicity. Final vital status
was unknown for 18 infants who were still in the hospital at 120 days and 11 infants who were transferred to
another facility after 7 to 192 days in the birth hospital, with most transferred after 33 to 58 days. In the
2008-2012 cohort, final vital status was unknown for 44 (0.5%) of 8877 infants. In the prior report, these
infants were assumed to have survived to discharge. Without this assumption, survival to discharge would
change from 6746 (76.0%) of 8877 to 6702 (75.9%) of 8833.

26/1826 (1.4)

1582/1826 (86.6)

1608/1826 (88.1)

1788 (97.9)

1827

26/1835 (1.4)

1582/1835 (86.2)

1608/1835 (87.6)

1788 (97.4)

1836

b

21/1584 (1.3)

1245/1584 (78.6)

1266/1584 (79.9)

1546 (97.3)

1589

21/1599 (1.3)

1245/1599 (77.9)

1266/1599 (79.2)

1546 (96.4)

1604

Data are from Stoll et al.1 Infants included were restricted to those with birth weights of 401 g to 1500 g,
consistent with Neonatal Research Network eligibility criteria during prior years. This criterion primarily
restricted eligibility for infants born at 22 weeks’ gestational age. The current cohort includes infants born at
22-28 weeks’ gestational age with any birth weight, including 163 (1.5%) with birth weights less than 401 g and
79 (0.7%) with birth weights greater than 1500 g.

24/1362 (1.8)

948/1362 (69.6)

972/1362 (71.4)

1298 (94.8)

1369

24/1391 (1.7)

948/1391 (68.2)

972/1391 (69.9)

1298 (92.8)

1398

a

15/958 (1.6)

520/958 (54.3)

856 (89.4)

201

Survived >12 h

958

15/1083 (1.4)

No.

Infants actively treated at birthd

535/1083 (49.4)

60/549 (10.9)

Survived to discharge
or 1 yc
520/1083 (48.0)

856 (79.0)

159 (28.9)

1083

550

Survived >12 h

24

22-28

23

22

No.

All infants

2008-2012a

2013-2018

No./total (%), by gestational age, in weeks

Table 2. Survival of Infants Born at 22-28 Weeks’ Gestational Age in 2013-2018 for All Infants and Infants Actively Treated at Birth
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discharge increased significantly with gestational age (P < .001)
(Table 2; eFigure 2 in Supplement 1). Of live-born infants at 22
weeks, 10.9% (60/549) survived compared with 6.6% (22/
334) in 2008-2012 (difference, 4.3%; 95% CI, 0.6%-8.1%;
P = .03); at 23 weeks, survival increased significantly to 49.4%
(535/1083) from 32.3% (252/779) in 2008-2012 (difference,
17.1%; 95% CI, 12.6%-21.5%; P < .001).1 Survival at 28 weeks
was 94.0% (2267/2412). Only 36.5% of infants born at 22 weeks’
gestational age were actively treated, but 88.5% born at 23
weeks, 97.9% born at 24 weeks, and more than 99% born at
25-28 weeks received active treatment. Although only 10.9%
of infants live-born at 22 weeks survived to discharge or 1 year,
30.0% (60/200) of those actively treated survived. Among
those born at 23 weeks, 49.4% of all live-born infants and 55.8%
(535/958) of actively treated infants survived.

Treatments and Morbidities During Initial Hospitalization
Delayed umbilical cord clamping or cord milking was documented for 40.6% (1982/4881) of births (Table 3). Treatments
including intubation/ventilation, nutrition/hydration, and/or
medication were withheld, limited, or withdrawn for 10.1%
(1005/9956) of infants at some time after 12 hours of age.
A total of 84.3% (8388/9951) of infants who survived
more than 12 hours underwent mechanical ventilation during
the hospitalization, and 79.8% received surfactant; these proportions varied significantly with gestational age (P < .001 for
each). Overall, 18.6% (1791/9624) of infants received postnatal corticosteroids for bronchopulmonary dysplasia, 10.1%
(1009/9959) of infants received inhaled nitric oxide, and
18.4% (1799/9796) received vitamin A; proportions varied
significantly by gestational age (P < .001 for each). Medication was given to 23.4% (2331/9954) of infants for closure of a
patent ductus arteriosus, and 7.4% (741/9953) had surgery or
cardiac catheterization for patent ductus arteriosus closure.
Overall, 78.4% (7807/9960) of infants underwent transfusion
with red blood cells; more than 95% of infants born at 22-25
weeks’ gestational age had transfusion, as did 49.3% (7807/
9960) of those born at 28 weeks. Probiotics were received by
9.6% (443/4630) of infants, but use varied by center; no
infants received probiotics at 12 centers, less than 6%
received probiotics at 4 centers, and more than 30% received
probiotics at 3 centers. Overall, 91.7% (9019/9830) of infants
received human milk in the first 28 days of life. Parenteral
nutrition was received for a median of 17 (IQR, 11-30) days.
Infants remained in the hospital for a median of 88 (IQR,
63-117) days; those born at 23-25 weeks’ gestation had
median hospital stays of 104 to 121 days. The median length
of hospitalization for all surviving infants was 93 (IQR,
72-122) days.
The proportion of infants diagnosed as having each morbidity during the birth hospitalization varied significantly by
gestational age (P < .001 for each) (Table 3). Necrotizing
enterocolitis was diagnosed in 8.9% (890/9956) of infants,
and 3.9% (386/9956) received surgery. Early-onset sepsis
and/or meningitis was diagnosed in 2.4% (238/9957) of
infants. Late-onset sepsis and/or meningitis was diagnosed in
19.9% (1911/9610) of infants surviving more than 72 hours.
The overall incidence of severe intracranial hemorrhage was
254

14.3% (1386/9705); severe intracranial hemorrhage was diagnosed in 38.2% (52/136) of infants born at 22 weeks compared with 5.3% (123/2342) born at 28 weeks (difference,
33.0%; 95% CI, 25.2%-41.4%; P < .001). Cystic periventricular
leukomalacia was diagnosed in 4.6% (444/9731) of infants.
The overall incidence of retinopathy of prematurity was
54.9% (4713/8585); 12.8% (1099/8585) had severe retinopathy of prematurity (stage ≥3). Retinopathy of prematurity was
diagnosed in 92.9% (65/70) of infants born at 22 weeks compared with 29.8% (660/2216) of those born at 28 weeks (difference, 63.1%; 95% CI, 54.4%-67.7%; P < .001). Of the
infants who survived to 36 weeks’ postmenstrual age, 49.8%
(4307/8641) had bronchopulmonary dysplasia based on continued oxygen use, including more than 75% of infants of
22-24 weeks’ gestational age. Based on the mode of support
received at 36 weeks’ postmenstrual age,21 60.7% (5045/
8305) of infants had bronchopulmonary dysplasia of grade 1
or higher and 8.0% (666/8305) had grade 3. The distribution
of bronchopulmonary dysplasia grade differed by gestational
age (P < .001). Infants received respiratory support for a
median of 41 days, decreasing significantly from 93 days at
22 weeks to 17 days at 28 weeks.
Compared with the 2008-2012 cohort reported by Stoll
et al,1 the incidence of necrotizing enterocolitis in the present
cohort was significantly lower (8.9% vs 10.3%; adjusted difference, −1.6%; 95% CI, −2.5% to −0.8%), as was the incidence of late-onset sepsis and/or meningitis (19.9% vs 24.4%;
adjusted difference, −4.9%; 95% CI, −6.0% to −3.7%), severe
intracranial hemorrhage (14.3% vs 14.6%; adjusted difference, −1.0%; 95% CI, −1.9% to −0.1%), and retinopathy of prematurity (54.9% vs 56.3%; adjusted difference, −2.1; 95% CI,
−3.5% to −0.7%). The incidence of bronchopulmonary dysplasia (supplemental oxygen use at 36 weeks’ postmenstrual
age) was significantly higher (49.8% vs 44.7%; adjusted difference, 4.3%; 95% CI, 2.8%-5.8%) in the present cohort
(Table 3). There was no significant difference between the
current cohort and the 2008-2012 cohort in the incidence of
early-onset sepsis and/or meningitis, cystic periventricular
leukomalacia, or severe retinopathy of prematurity.

Outcomes at 22-26 Months’ Corrected Age for Infants Born
in 2013-2016
Among 2930 surviving infants born in 2013-2016 at gestational ages of 22-26 weeks who were eligible for follow-up,
2566 (87.6%) were seen at visits between January 22, 2015,
and August 13, 2019, and were included in analysis of outcomes (eFigure 1 in Supplement 1); 2458 infants (83.9%) had
all information needed to complete the NDI evaluation.
Mothers of children seen at follow-up had an older median
age and were more likely to have a college degree and to be of
Black or White race compared with those lost to follow-up,
and more children seen at follow-up were born at lower gestational ages and with lower birth weights (eTable 1 in
Supplement 1).
A total of 48.7% (1198/2458) of the children evaluated
had no or mild NDI, 29.3% (709/2419) had moderate NDI, and
21.2% (512/2419) had severe NDI (Figure, A; eTable 2 in
Supplement 1). For infants born at 23-26 weeks’ gestation,
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Variables

25 (n = 1546)

26 (n = 1788)

27 (n = 1943)

190/1544 (12.3)

296/756 (39.2)

121/1787 (6.8)

344/859 (40.0)

97/1941 (5.0)

402/930 (43.2)

954/2374 (40.2)

66/2371 (2.8)

523/1163 (45.0)

6342/9963 (63.7)

1005/9956 (10.1)

1982/4881 (40.6)
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159/159 (100.0) 855/856 (99.9) 1282/1298 (98.8) 1476/1545 (95.5) 1579/1786 (88.4) 1466/1940 (75.6) 1571/2367 (66.4) 8388/9951 (84.3) 6983/8030 (87.0) −2.1 (−3.2 to −0.9)

Mechanical ventilation
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11/158 (7.0)

133

Early-onset sepsis
and/or meningitisj

Infants surviving >3 d

136/159 (85.5)

Intracranial hemorrhage 52/136 (38.2)
grade III or IVk

Cranial sonogram
within 28 d

61/132 (46.2)

12/159 (7.5)

Surgery for NEC

Late-onset sepsis
and/or meningitisj

19/159 (11.9)

NEC stage ≥IIAi

Morbidities during
hospitalization

91/837 (10.9)

89/908 (9.8)

125/1141 (11.0)

47/2374 (2.0)

443/4630 (9.6)

741/9953 (7.4)

25 (14-40)
[n = 1297]

22 (14-35)
[n = 1545]

18 (13-30)
[n = 1788]

15 (11-24)
[n = 1938]

13 (10-20)
[n = 2373]

17 (11-30)
[n = 9954]

12/1298 (0.9)

1216

52/1298 (4.0)

82/1298 (6.3)

379/1479 (25.6)

1481

39/1545 (2.5)

78/1544 (5.1)

178/1544 (11.5)

16/1545 (1.0)

322/1752 (18.4)

1753

31/1787 (1.7)

48/1787 (2.7)

144/1787 (8.1)

18/1788 (1.0)

242/1911 (12.7)

1913

38/1941 (2.0)

47/1941 (2.4)

140/1941 (7.2)

11/1941 (0.6)

181/2343 (7.7)

2347

29/2372 (1.2)

41/2373 (1.7)

129/2373 (5.4)

4/2374 (0.2)

7738

165/8032 (2.1)

0.2 (−0.2 to 0.6)

1911/9610 (19.9) 1890/7737 (24.4) −4.9 (−6.0 to −3.7)

9622

238/9957 (2.4)

386/9956 (3.9)

890/9956 (8.9)

67/9961 (0.7)

298/819 (36.4) 308/1251 (24.6)

260/1500 (17.3)

202/1752 (11.5)

143/1905 (7.5)

123/2342 (5.3)

(continued)

1386/9705 (14.3) 1149/7851 (14.6) −1.0 (−1.9 to −0.1)

819/855 (95.8) 1251/1298 (96.4) 1501/1545 (97.2) 1752/1788 (98.0) 1905/1941 (98.1) 2343/2375 (98.7) 9707/9961 (97.5) 7852/8034 (97.7) −0.2 (−0.6 to 0.3)

319/778 (41.0) 407/1215 (33.5)

779

38/856 (4.4)

78/854 (9.1)

130/854 (15.2) 150/1298 (11.6)

5/856 (0.6)

837/856 (97.8) 1267/1298 (97.6) 1471/1544 (95.3) 1561/1788 (87.3) 1345/1941 (69.3) 1170/2374 (49.3) 7807/9960 (78.4)

25 (12-44)
[n = 855]

−1.6 (−2.5 to −0.8)

156/159 (98.1)

Red blood cell transfusion

53/715 (7.4)

73/1941 (3.8)

2331/9954 (23.4)

711/848 (83.8) 1140/1282 (88.9) 1369/1514 (90.4) 1661/1760 (94.4) 1820/1928 (94.4) 2202/2339 (94.1) 9019/9830 (91.7)

41/570 (7.2)

119/1787 (6.7)

272/2374 (11.5)

825/8032 (10.3)

15 (7-38)
[n = 158]

Parenteral nutrition,
median (IQR), d

1/159 (0.6)

116/159 (73.0)

Receipt of human milk
in first 28 dh

Tracheostomy

31/391 (7.9)

13/68 (19.1)

Probioticse

169/1543 (11.0)

316/1941 (16.3)

1009/9959 (10.1)
1799/9796 (18.4)

121/855 (14.2) 192/1295 (14.8)

462/1786 (25.9)

202/2315 (8.7)

108/2374 (4.5)

4.0 (3.1 to 4.9)

20/158 (12.7)
Patent ductus arteriosus
surgery or cardiac
catheterization for closure

480/1544 (31.1)

279/1910 (14.6)

126/1941 (6.5)

1791/9624 (18.6) 971/7936 (12.2)

278/855 (32.5) 487/1296 (37.6)

370/1758 (21.0)

147/1788 (8.2)

110/2359 (4.7)

36/158 (22.8)

340/1531 (22.2)

171/1544 (11.1)

197/1913 (10.3)

Patent ductus arteriosus
medicationg

229/848 (27.0) 309/1275 (24.2)

172/856 (20.1) 230/1297 (17.7)

284/1724 (16.5)

55/159 (34.6)

379/1470 (25.8)

70/159 (44.0)

328/808 (40.6) 443/1196 (37.0)

849/856 (99.2) 1241/1298 (95.6) 1407/1546 (91.0) 1480/1788 (82.8) 1364/1943 (70.2) 1458/2376 (61.4) 7957/9966 (79.8)

248/856 (29.0) 226/1298 (17.4)

146/450 (32.4) 233/637 (36.6)

28 (n = 2376)

Vitamin A

Postnatal corticosteroid
(systemic)

24 (n = 1298)

818/856 (95.6) 1123/1298 (86.5) 1215/1546 (78.6) 1133/1787 (63.4) 946/1943 (48.7)

23 (n = 856)

Adjusted
difference
22-28 (n = 9966) 22-28 (n = 8034) (95% CI)d
2008-2012c

Inhaled nitric oxide

158/159 (99.4)

50/154 (32.5)

Surfactant

57/159 (35.8)

Treatments withheld,
limited, or withdrawn
to limit caref

Interventions during
hospitalization

153/159 (96.2)

38/86 (44.2)

Delayed umbilical cord
clamping or cord milkinge

22 (n = 159)

2013-2018

Delivery room intubation

Peridelivery interventions

a

No./total (%), by gestational age in weeksb

Table 3. In-Hospital Treatments and Outcomes for Infants Surviving More Than 12 Hours After Birth
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22/70 (31.4)

19/69 (27.5)

Severe ROP
(stage ≥3)

Intervention
and/or treatment
for ROPl
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36/64 (56.3)

Grade 2

13/64 (20.3)

9/64 (14.1)

Grade 1

Grade 3

6/64 (9.4)

No BPD

Mode of support
at 36 wko

Oxygen use at 36 wkn 50/64 (78.1)

Evaluation for BPD

145/984 (14.7)

100/553 (18.1) 165/984 (16.8)

209/553 (37.8) 316/984 (32.1)

198/553 (35.8) 358/984 (36.4)

46/553 (8.3)

470/557 (84.4) 769/1009 (76.2)

1015

316/564 (56.0) 551/1003 (54.9)

51/70 (72.9)

Undetermined
in either eye
(neither eye with
severe ROP)
559

153/564 (27.1) 197/1003 (19.6)

13/70 (18.6)

Determined,
severe ROP
in 1 or both eyes

64

95/564 (16.8)

255/1003 (25.4)

180/566 (31.8) 242/1009 (24.0)

216/567 (38.1) 322/1013 (31.8)

499/567 (88.0) 871/1013 (86.0)

6/70 (8.6)

Infants surviving to 36 wk
postmenstrual agem

27 (n = 1943)

1352

96/1505 (6.4)

1655

70/1755 (4.0)

1813

57/1911 (3.0)

23/1905 (1.2)

28 (n = 2376)

2254

48/2351 (2.0)

16/2342 (0.7)

8813

444/9731 (4.6)

144/9706 (1.5)

123/1266 (9.7)

340/1266 (26.9)

488/1266 (38.5)

315/1266 (24.9)

837/1296 (64.6)

1302

749/1284 (58.3)

132/1284 (10.3)

403/1284 (31.4)

164/1299 (12.6)

249/1307 (19.1)

922/1307 (70.5)

116/1554 (7.5)

347/1554 (22.3)

518/1554 (33.3)

573/1554 (36.9)

822/1629 (50.5)

1634

914/1588 (57.6)

85/1588 (5.4)

589/1588 (37.1)

96/1611 (6.0)

166/1626 (10.2)

944/1626 (58.1)

660/2216 (29.8)

21/2088 (1.0)

859/2088 (41.1)

20/2208 (0.9)

45/2216 (2.0)

97/1725 (5.6)

278/1725 (16.1)

500/1725 (29.0)

850/1725 (49.3)

722/1814 (39.8)

1823

633/8333 (7.6)

2892/8333 (34.7)

761/8539 (8.9)

52/2159 (2.4)

216/2159 (10.0)

566/2159 (26.2)

6909

0.5 (−0.1 to 1.2)

666/8305 (8.0)

1742/8305 (21.0)

2637/8305 (31.8)

(continued)

4307/8641 (49.8) 3064/6853 (44.7) 4.3 (2.8 to 5.8)

8688

1325/2159 (61.4) 3260/8305 (39.3)

637/2272 (28.0)

2291

−0.2 (−0.8 to 0.3)

4713/8585 (54.9) 3821/6789 (56.3) −2.1 (−3.5 to −0.7)

352/7872 (4.5)

1099/8585 (12.8) 839/6789 (12.4)

1019/1736 (58.7) 1208/2088 (57.9) 4808/8333 (57.7)

32/1736 (1.8)

685/1736 (39.5)

40/1777 (2.3)

79/1786 (4.4)

752/1786 (42.1)

568/609 (93.3) 1013/1053 (96.2) 1307/1351 (96.7) 1626/1655 (98.2) 1786/1811 (98.6) 2216/2253 (98.4) 8586/8809 (97.5)

609

Determined,
favorable
in both eyes

ROP status at
discharge, transfer,
death, or 120 d

65/70 (92.9)

70/77 (90.9)

77

103/1254 (8.2)

24/1752 (1.4)

64/820 (7.8)

26 (n = 1788)

6/135 (4.4)

24/1501 (1.6)

821/855 (96.0) 1255/1298 (96.7) 1507/1545 (97.5) 1756/1788 (98.2) 1913/1941 (98.6) 2353/2375 (99.1) 9741/9961 (97.8) 7876/8034 (98.0) −0.1 (−0.5 to 0.3)

25 (n = 1546)

136/159 (85.5)

33/1251 (2.6)

21/819 (2.6)

24 (n = 1298)

23 (n = 856)

3/136 (2.2)

Adjusted
difference
22-28 (n = 9966) 22-28 (n = 8034) (95% CI)d
2008-2012c

22 (n = 159)

ROP

ROP examination

Infants still hospitalized
at 28 d

Finding of cystic
periventricular
leukomalacia

Cranial imaging
within 28 d
or after 28 d
and closest to 36 wk
postmenstrual age

Shunt for
posthemorrhagic
hydrocephalus

Variablesa

2013-2018

No./total (%), by gestational age in weeksb

Table 3. In-Hospital Treatments and Outcomes for Infants Surviving More Than 12 Hours After Birth (continued)
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65 (50-81)
[n = 64]

Invasive only

156 (135-217)
[n = 60]

Surviving infants only

143 (122-175)
[n = 535]

121 (18-156)
[n = 856]

51 (36-70)
[n = 557]

81 (69-88)
[n = 555]

23 (n = 856)

127 (108-156)
[n = 972]

115 (82-148)
[n = 1298]

37 (23-57)
[n = 1003]

71 (57-81)
[n = 996]

24 (n = 1298)

Data are expressed as No./total (%) of infants unless otherwise indicated.

From Stoll et al.1 Infants included were restricted to those with birth weights of 401 g to 1500 g, consistent with
Neonatal Research Network eligibility criteria during prior years. This criterion primarily restricted eligibility for
infants born at 22 weeks’ gestational age. The current cohort includes infants born at 22-28 weeks’ gestational
age with any birth weight, including 163 (1.5%) with birth weights less than 401 g and 79 (0.7%) with birth
weights greater than 1500 g.

Where possible given data reported by Stoll et al, differences adjusted for gestational age are shown between
the proportion reported for infants born at 22-28 weeks’ gestational age in the 2013-2018 cohort vs in
2008-2012 along with associated 95% confidence intervals for the difference. A positive difference indicates
that the proportion increased in the 2013-2018 cohort compared with the 2008-2012 cohort; a negative
difference indicates that the proportion decreased in the 2013-2018 cohort compared with the earlier cohort.

Collected beginning in 2016.

Treatments included intubation/ventilation, nutrition/hydration, and/or medication.

Patent ductus arteriosus medication included indomethacin, ibuprofen, and acetaminophen.

Human milk includes both maternal and donor milk.

Bell18 staging of necrotizing enterocolitis (NEC) as modified by Walsh and Kliegman19: stage IA, suspected NEC
without gross hematochezia; stage IB, suspected NEC with gross hematochezia; stage IIA, definite NEC, mildly
ill; stage IIB, definite NEC, moderately ill; stage IIIA, advanced NEC, severely ill, bowel intact; stage IIIB, advanced
NEC, severely ill, bowel perforated.

Early-onset (ⱕ72 hours) and late-onset (>72 hours) sepsis was defined by positive blood culture and appropriate
therapy for 5 or more days or intent to treat if death occurred within 5 days. Early-onset and late-onset

b

c

d

e

f

g

h

i

j

82 (68-99)
[n = 1787]

80 (65-98)
[n = 1943]

2 (0-9)
[n = 1812]

29 (12-45)
[n = 1810]

27 (n = 1943)

70 (57-85)
[n = 2267]

69 (56-85)
[n = 2376]

1 (0-5)
[n = 2276]

17 (6-32)
[n = 2268]

28 (n = 2376)

93 (72-122)
[n = 8495]

88 (63-117)
[n = 9966]

7 (1-31)
[n = 8634]

41 (19-62)
[n = 8600]

Adjusted
difference
22-28 (n = 9966) 22-28 (n = 8034) (95% CI)d
2008-2012c

jama.com

Downloaded From: https://jamanetwork.com/ by a University Of New Mexico User on 07/19/2022
For surviving infants who were discharged or transferred before 36 weeks’ postmenstrual age, BPD was defined
as supplemental oxygen use at 36 weeks if known or use at discharge or transfer. Of the 8641 infants evaluated,
7782 (90%) were still in the hospital at 36 weeks’ postmenstrual age, 541 (6%) had been discharged home, and
318 (4%) had been transferred to another hospital after a median of 41 days in the birth hospital.
Based on the optimal definition (definition 15) from Jensen et al.21 This definition classifies BPD based on the
mode of support received at 36 weeks’ postmenstrual age or at discharge home if earlier: no BPD, no support or
breathing room air; grade 1, nasal cannula at a flow rate of 2 L/min or less; grade 2, nasal cannula at a flow rate of
more than 2 L/min or noninvasive positive airway pressure; and grade 3, invasive mechanical ventilation. BPD
was undefined for infants transferred prior to 36 weeks’ postmenstrual age unless status at 36 weeks was
known. Of the 8305 infants evaluated, 7764 (93%) were still in the hospital at 36 weeks’ postmenstrual age, 538
(6%) had been discharged home, and 3 (<1%) had been transferred to another hospital.
Total includes high-frequency ventilation, conventional ventilation, nasal intermittent positive pressure
ventilation, and/or continuous positive airway pressure. Invasive includes high-frequency and/or conventional
ventilation.

n

o

p

Infants surviving to 36 weeks’ postmenstrual age include infants still in the hospital at 36 weeks (90%) or
discharged home or transferred before 36 weeks.

Interventions and treatments for ROP included any of retinal ablation (laser and/or cryotherapy), scleral buckle,
vitrectomy, and/or bevacizumab or other antivascular endothelial growth factor therapies.

l

m

Intracranial hemorrhage was determined based on the cranial sonogram with the most severe findings
performed within 28 days after birth and was classified by the criteria of Papile et al20: grade I, subependymal
hemorrhage; grade II, intraventricular hemorrhage without ventricular dilatation; grade III, intraventricular
hemorrhage with ventricular dilatation; grade IV, intraventricular hemorrhage with parenchymal hemorrhage.

k

meningitis were defined by positive cerebrospinal fluid culture and appropriate therapy for 7 or more days or
intent to treat if death occurred within 7 days. In 2008-2012, the reported proportions of early-onset and
late-onset sepsis did not include meningitis. In the current cohort, 2 (0.8%) of 238 infants with early-onset
sepsis and/or meningitis had meningitis alone. Of the 1911 infants with late-onset sepsis and/or meningitis, 24
(1.3%) had meningitis alone.

96 (80-118)
[n = 1608]

93 (75-116)
[n = 1788]

8 (2-26)
[n = 1627]

44 (28-61)
[n = 1617]

26 (n = 1788)

Distributions of the variables reported differed significantly across gestational age; adjusted P < .01 for all except
adjusted P = .04 for tracheostomy, by Wald χ2, likelihood ratio χ2, or F test, adjusting for study center, small for
gestational age, male sex, multiple gestation, and maternal race and ethnicity. Study center could not be
included in models fit to vitamin A use and probiotic use because some centers reported no use.

110 (93-134)
[n = 1266]

104 (83-129)
[n = 1546]

23 (7-40)
[n = 1295]

57 (43-72)
[n = 1291]

25 (n = 1546)

a

Abbreviations: BPD, bronchopulmonary dysplasia; ROP, retinopathy of prematurity.

26 (7-142)
[n = 159]

All patients

Length of hospitalization,
median (IQR), d

93 (81-95)
[n = 63]

22 (n = 159)

Total

Assisted ventilation
by 36 wk
postmenstrual age,
median (IQR), dp

Variablesa

2013-2018

No./total (%), by gestational age in weeksb

Table 3. In-Hospital Treatments and Outcomes for Infants Surviving More Than 12 Hours After Birth (continued)
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Figure. Neurodevelopmental Impairment at 22-26 Months’ Corrected Age in Children Born at 22-26 Weeks’ Gestational Age During 2013-2016
A Degrees of NDI

B

100

Death and NDI
100
Died before discharge

Severe NDI
80

Moderate NDI

Died after discharge

80

Survived with severe NDI

No or mild NDI

Children, %

Children, %

Survived with moderate NDI
60

40

20

60

Survived with no or mild NDI

40

20

0

0
22
n = 29

23
n = 284

24
n = 551

25
n = 702

26
n = 892

22
n = 112

22-26
n = 2458

23
n = 571

Gestational age, wk
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24
n = 828

25
n = 921

26
n = 1096

22-26
n = 3500

Gestational age, wk

A, Neurodevelopmental impairment (NDI) among 2458 children evaluated at
22-26 months’ corrected age. Mild or no NDI was defined as a Bayley Scales of
Infant and Toddler Development, Third Edition (Bayley-III) cognitive composite
score of 85 or higher, a Bayley-III motor composite score of 85 or higher, and
Gross Motor Function Classification System (GMFCS)25 level 0 or 1. Moderate
NDI was defined as any of a Bayley-III cognitive composite score or motor
composite score of 70 to 84 or GMFCS level 2 or 3. Severe NDI was defined by
any of a Bayley-III cognitive composite score or motor composite score less than
70, GMFCS level 4 or 5, bilateral blindness, or severe hearing impairment
(see Table 4 footnotes b and d for more details).

B, Death and NDI at 22-26 months’ corrected age among children born at 22-26
weeks’ gestational age who were actively treated at birth. Children born at
22-26 weeks’ gestational age were eligible for a follow-up assessment at 22-26
months’ corrected age. Proportions are shown for the 3500 children actively
treated at birth who had died by 22-26 months’ corrected age or were seen at
follow-up and evaluated for NDI. Active treatment was defined as intubation,
surfactant therapy, respiratory support, chest compressions, epinephrine,
volume resuscitation, blood pressure support, or parenteral nutrition22
(see Table 4 footnotes b and d for more details).

the proportion with no or mild NDI increased significantly
from 31.0% (88/284) at 23 weeks to 58.1% (518/892) at 26
weeks (difference, 27.1%; 95% CI, 20.6%-33.2%; P < .001). Of
29 infants born at 22 weeks’ gestation and evaluated for NDI,
13 (44.8%) had no or mild NDI, 7 (24.1%) had moderate NDI,
and 9 (31.0%) had severe NDI. eFigure 3 in Supplement 1
shows a complete accounting of all infants who were eligible
for follow-up assessment, including those who died before
assessment or were lost to follow-up. The proportions of children who died or who survived with varying degrees of NDI
are shown for all children who died or were evaluated (eFigure 4 in Supplement 1) and for the subset of children who
were actively treated at birth (Figure, B).
Mean Bayley-III cognitive, language, and motor composite scores differed significantly overall by gestational age
(P < .001 for each) (Table 4; eFigures 5-7 in Supplement 1).
The proportion of children with cognitive composite scores
of less than 70 decreased from 25.8% (8/31) for those born at
22 weeks to 8.3% (75/905) for those born at 26 weeks (difference, −17.5%; 95% CI, −35.1% to −5.2%; P < .001). Twentyfive percent (607/2431) of children had Bayley-III language
composite scores of less than 70, with higher proportions
among those born at 23 and 24 weeks. Seven of 30 children
(23.3%) born at 22 weeks had a motor composite score of less
than 70, while the proportions were 29.1% (81/278) for those
born at 23 weeks and 9.6% (85/882) for those born at 26
weeks. Among children born at 22, 23, or 24 weeks’ gestational age, mean cognitive, language, and motor scores were
significantly lower for those born at 23 weeks compared with
those born at 24 weeks (P < .01 for each), but statistically significant differences were not found between scores for chil-

dren born at 22 weeks’ gestational age compared with those
born at 23 or 24 weeks (Table 4; eFigures 5-7 in Supplement 1). The proportion of children with language and motor
scores of less than 70 was significantly higher for children
born at 23 weeks’ gestational age compared with those born
at 24 weeks (P = .006 and P = .03, respectively), but the proportion with cognitive scores of less than 70 did not differ
among children born at 22, 23, or 24 weeks (P = .20).
The proportion of children with cerebral palsy of any
severity was 17.9% (457/2555) and decreased significantly
from 48.4% (15/31) among those born at 22 weeks to 11.9%
(112/938) among those born at 26 weeks (difference, −36.5%;
95% CI, −53.4% to −19.9%; P < .001) (Table 4). Most of
the affected children had mild cerebral palsy, but 2.1% to
9.7% had severe cerebral palsy, varying inversely with gestational age. Overall, 1.5% (38/2555) of children had blindness in both eyes; 2.5% (64/2527) used hearing aids or cochlear implants.
A total of 49.9% (1277/2561) of children were rehospitalized after initial discharge. The 1277 children who were
rehospitalized had 2980 admissions. Respiratory disease
was the most common reason for readmission (54.0%), followed by surgery (15.4%) and infection (9.3%) (eTable 3 in
Supplement 1).
By 22-26 months’ corrected age, 81.6% (2090/2561) of
children were feeding themselves independently; this proportion varied significantly with gestational age (P < .001)
(Table 4). Oral feeding requiring more than occasional assistance was reported for 7.3% (187/2561) of children. Limited
oral feeding requiring some food by an alternate route or
no oral feeding was reported for 11.1% (284/2561).
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Table 4. Outcomes at 22-26 Months’ Corrected Age for Children Born at 22-26 Weeks’ Gestational Age in 2013-2016
No./total (%), by gestational age in weeksa
Variables

22 (n = 31)

23 (n = 292)

24 (n = 567)

25 (n = 733)

26 (n = 943)

22-26 (n = 2566)

Bayley-III scoresb
Cognitive composite score
No. evaluated

31

285

559

712

905

2492

Mean (SD)

80.0 (16.4)

79.7 (16.8)

82.0 (15.7)

86.3 (15.1)

88.4 (14.6)

85.3 (15.6)

Median (IQR)

85 (65-90)

80 (70-90)

85 (70-95)

90 (80-95)

90 (80-95)

85 (75-95)

<70

8 (25.8)

68 (23.9)

117 (20.9)

89 (12.5)

75 (8.3)

357 (14.3)

70-84

6 (19.4)

82 (28.8)

145 (25.9)

163 (22.9)

207 (22.9)

603 (24.2)

≥85

17 (54.8)

135 (47.4)

297 (53.1)

460 (64.6)

623 (68.8)

1532 (61.5)

Language composite score
No. evaluated

31

282

544

696

878

2431

Mean (SD)

78.6 (19.0)

75.0 (17.8)

77.6 (17.7)

82.3 (17.4)

84.4 (16.7)

81.1 (17.6)

Median (IQR)

79 (71-94)

74 (62-89)

79 (65-89)

83 (71-94)

86 (74-97)

83 (71-94)

<70

7 (22.6)

111 (39.4)

177 (32.5)

151 (21.7)

161 (18.3)

607 (25.0)

70-84

11 (35.5)

74 (26.2)

155 (28.5)

214 (30.7)

241 (27.4)

695 (28.6)

≥85

13 (41.9)

97 (34.4)

212 (39.0)

331 (47.6)

476 (54.2)

1129 (46.4)

Motor composite score
No. evaluated

30

278

539

697

882

2426

Mean (SD)

76.6 (18.4)

76.7 (17.8)

80.2 (16.5)

85.7 (15.5)

88.6 (15.0)

84.4 (16.4)

Median (IQR)

84 (70-91)

79 (64-88)

82 (70-91)

88 (79-97)

91 (82-97)

88 (76-94)

<70

7 (23.3)

81 (29.1)

123 (22.8)

87 (12.5)

85 (9.6)

383 (15.8)

70-84

8 (26.7)

87 (31.3)

151 (28.0)

175 (25.1)

181 (20.5)

602 (24.8)

≥85

15 (50.0)

110 (39.6)

265 (49.2)

435 (62.4)

616 (69.8)

1441 (59.4)

None

16/31 (51.6)

197/290 (67.9)

432/566 (76.3)

627/730 (85.9)

826/938 (88.1)

2098/2555 (82.1)

Mild

8/31 (25.8)

41/290 (14.1)

73/566 (12.9)

56/730 (7.7)

65/938 (6.9)

243/2555 (9.5)

Moderate

4/31 (12.9)

27/290 (9.3)

40/566 (7.1)

24/730 (3.3)

27/938 (2.9)

122/2555 (4.8)

Severe

3/31 (9.7)

25/290 (8.6)

21/566 (3.7)

23/730 (3.2)

20/938 (2.1)

92/2555 (3.6)

0

12/31 (38.7)

145/289 (50.2)

336/565 (59.5)

536/731 (73.3)

731/937 (78.0)

1760/2553 (68.9)

1

11/31 (35.5)

83/289 (28.7)

151/565 (26.7)

132/731 (18.1)

146/937 (15.6)

523/2553 (20.5)

2 or 3

5/31 (16.1)

39/289 (13.5)

56/565 (9.9)

39/731 (5.3)

39/937 (4.2)

178/2553 (7.0)

4 or 5

3/31 (9.7)

22/289 (7.6)

22/565 (3.9)

24/731 (3.3)

21/937 (2.2)

92/2553 (3.6)

Normal in both eyes

22/31 (71.0)

204/289 (70.6)

460/566 (81.3)

629/731 (86.0)

856/938 (91.3)

2171/2555 (85.0)

Corrective lenses/other abnormality
but not blind in either eye

5/31 (16.1)

75/289 (26.0)

94/566 (16.6)

91/731 (12.4)

74/938 (7.9)

339/2555 (13.3)

Blind in 1 eye

1/31 (3.2)

2/289 (0.7)

3/566 (0.5)

1/731 (0.1)

0/938 (0.0)

7/2555 (0.3)

Blind in both eyes

3/31 (9.7)

8/289 (2.8)

9/566 (1.6)

10/731 (1.4)

8/938 (0.9)

38/2555 (1.5)

Cerebral palsyc

GMFCS leveld

Visione

Hearingf
No functional impairment

29/30 (96.7)

271/285 (95.1)

544/560 (97.1)

707/724 (97.7)

907/929 (97.6)

2458/2528 (97.2)

Functional impairment

1/30 (3.3)

14/285 (4.9)

16/560 (2.9)

17/724 (2.3)

22/929 (2.4)

70/2528 (2.8)

Cochlear implant or aid

0/30 (0.0)

8/285 (2.8)

13/561 (2.3)

16/722 (2.2)

27/929 (2.9)

64/2527 (2.5)

20/31 (64.5)

171/290 (59.0)

311/567 (54.9)

360/732 (49.2)

415/941 (44.1)

1277/2561 (49.9)

3 (2-4)

2 (1-3)

2 (1-3)

2 (1-3)

1 (1-3)

2 (1-3)

Independently feeds self

20/31 (64.5)

208/290 (71.7)

436/567 (76.9)

622/732 (85.0)

804/941 (85.4)

2090/2561 (81.6)

Dependent oral feeding

5/31 (16.1)

30/290 (10.3)

50/567 (8.8)

45/732 (6.1)

57/941 (6.1)

187/2561 (7.3)

Limited oral feeding

5/31 (16.1)

38/290 (13.1)

59/567 (10.4)

51/732 (7.0)

62/941 (6.6)

215/2561 (8.4)

No oral feeding

1/31 (3.2)

14/290 (4.8)

22/567 (3.9)

14/732 (1.9)

18/941 (1.9)

69/2561 (2.7)

Medical history and functional outcomes
Had a hospitalization after discharge
No. of hospitalizations,
median (IQR)
Oral motor skills

(continued)
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Table 4. Outcomes at 22-26 Months’ Corrected Age for Children Born at 22-26 Weeks’ Gestational Age in 2013-2016 (continued)
No./total (%), by gestational age in weeksa
Variables

22 (n = 31)

23 (n = 292)

24 (n = 567)

25 (n = 733)

26 (n = 943)

22-26 (n = 2566)

Current medical equipment
Apnea monitor

0/31 (0.0)

8/290 (2.8)

9/567 (1.6)

8/732 (1.1)

14/941 (1.5)

39/2561 (1.5)

Oxygen

3/31 (9.7)

33/290 (11.4)

33/567 (5.8)

36/732 (4.9)

30/941 (3.2)

135/2561 (5.3)

Ventilator or continuous positive
airway pressure

0/31 (0.0)

9/290 (3.1)

10/567 (1.8)

14/732 (1.9)

10/941 (1.1)

43/2561 (1.7)
294/2561 (11.5)

Gastrostomy or other tube feeding

6/31 (19.4)

52/290 (17.9)

81/567 (14.3)

75/732 (10.2)

80/941 (8.5)

Tracheostomy

1/31 (3.2)

19/290 (6.6)

29/567 (5.1)

23/732 (3.1)

22/941 (2.3)

94/2561 (3.7)

Pulse oximeter

3/31 (9.7)

42/290 (14.5)

57/567 (10.1)

48/732 (6.6)

41/941 (4.4)

191/2561 (7.5)

Any (≥1) of above

7/31 (22.6)

71/290 (24.5)

106/567 (18.7)

99/732 (13.5)

99/941 (10.5)

382/2561 (14.9)

Multiple (≥2) of above

3/31 (9.7)

44/290 (15.2)

58/567 (10.2)

46/732 (6.3)

41/941 (4.4)

192/2561 (7.5)

Adapted stroller or wheelchair

1/31 (3.2)

16/290 (5.5)

24/566 (4.2)

17/732 (2.3)

20/941 (2.1)

78/2560 (3.0)

Braces/orthotics

7/31 (22.6)

60/290 (20.7)

88/566 (15.5)

80/732 (10.9)

93/941 (9.9)

328/2560 (12.8)

Mobility aids/supportive equipment

Walker

4/31 (12.9)

24/290 (8.3)

23/566 (4.1)

22/732 (3.0)

21/941 (2.2)

94/2560 (3.7)

Stander

1/31 (3.2)

10/290 (3.4)

14/566 (2.5)

19/732 (2.6)

12/941 (1.3)

56/2560 (2.2)

Corner chair or other adaptive seat

1/31 (3.2)

9/290 (3.1)

7/566 (1.2)

7/732 (1.0)

5/941 (0.5)

29/2560 (1.1)

Any (≥1) of above

10/31 (32.3)

77/290 (26.6)

103/566 (18.2)

91/732 (12.4)

112/941 (11.9)

393/2560 (15.4)

Multiple (≥2) of above

3/31 (9.7)

32/290 (11.0)

32/566 (5.7)

35/732 (4.8)

29/941 (3.1)

131/2560 (5.1)

range is 47 to 153, and the motor composite score range is 46 to 154, with
lower scores representing more impaired outcomes.

Abbreviations: Bayley-III, Bayley Scales of Infant and Toddler Development,
Third Edition; GMFCS, Gross Motor Function Classification System.
a

b

Data are expressed as No./total (%) of children assessed at 22-26 months’
corrected age unless otherwise indicated. Corrected age represents age of
child based on expected date of delivery, calculated by subtracting the
number of weeks before 40 weeks of gestation at which birth occurred from
chronological age.15 To minimize the number of comparisons, differences in
Bayley-III composite scores by gestational age were tested for the mean
scores only. Similarly, differences by gestational age were not examined for
each item in the current medical equipment and mobility aids/supportive
equipment groups, but “any of above” was compared across gestational ages.
Vision data were analyzed as normal in both eyes vs the other categories
combined. For the purpose of assessing whether the proportion of infants
with a cochlear implant or hearing aid differed by gestational age, infants born
at 22 and 23 weeks’ gestational age were combined. Differences by gestational
age were significant for most outcomes; adjusted P < .001 except for adjusted
P = .12 for hearing impairment, adjusted P = .93 for cochlear implant or hearing
aid, and adjusted P = .29 for median number of hospitalizations after
discharge, adjusting for study center, small for gestational age, male sex,
multiple gestation, maternal race and ethnicity (Black, Hispanic, White,
or other), and maternal education assessed at the time of delivery (less than
high school degree, high school degree, more than high school degree,
or unknown).
Each Bayley-III composite score is standardized to a mean of 100 (SD, 15).The
cognitive composite score range is 55 to 145, the language composite score

At 22-26 months’ corrected age, 14.9% (382/2561) of children were using an apnea monitor, oxygen, ventilator or continuous positive airway pressure, feeding tube, tracheostomy, and/or pulse oximeter, with the proportion significantly
decreasing from 22.6% (7/31) of those born at 22 weeks’ gestational age to 10.5% (99/941) of those born at 26 weeks (difference, −12.1%; 95% CI, −29.4% to −0.6%; P < .001) (Table 4).
The most common assistive device used at 2 years’ corrected
age (11.5% [294/2561]) was a feeding tube (including gastrostomy). Oxygen was used by 5.3% (135/2561) of infants, and 1.7%
(43/2561) required a ventilator or continuous positive airway
pressure. In addition, 15.4% (393/2560) of children required
use of a mobility aid or other supportive equipment.
260

c

Mild cerebral palsy was defined as GMFCS level 1, moderate cerebral palsy as
GMFCS level 2 or 3, and severe cerebral palsy as GMFCS level 4 or 5.25

d

The GMFCS levels are defined as follows: level 0, walks independently, with
normal and fluent gait; level 1, walks 10 steps independently, but with some
gait abnormalities; level 2, maintains floor sitting but may need to use hands
for support to maintain balance, creeps on stomach or crawls on hands and
knees with reciprocal leg movement, may pull to stand and take steps holding
onto furniture; level 3, maintains floor sitting when the low back is supported,
rolls and creeps forward on stomach or may crawl with or without reciprocal
leg movements; level 4, has head control but trunk support is required for
floor sitting, can roll to supine, may roll to prone; and level 5, is unable to
maintain antigravity head and trunk postures in prone and sitting positions,
requires adult assistance to roll. Higher levels indicate greater limitation.

e

Vision in each eye was recorded as normal, having been prescribed corrective
lenses, other abnormality, blind (consistent with refraction of 20/200 or less)
with some functional vision, or no useful vision.

f

No functional hearing impairment was defined as being able to follow oral
directions given during the assessment, with or without amplification.
Functional hearing impairment was defined as permanent hearing loss that did
not permit a child to understand directions and communicate, with or without
amplification.

Discussion
Among extremely preterm infants born in 2013-2018 and
treated at 19 US academic medical centers, 78.3% survived to
discharge, a significantly higher rate than for infants born in
2008-2012.1 Rates of mortality and in-hospital morbidities were
higher among those born at earlier gestational ages. Among infants born at less than 27 weeks’ gestational age, rehospitalization and severe NDI were common at 2 years.
With improving survival of children born extremely preterm, there is increasing focus on broader outcomes including neurodevelopment. Although it is important to evaluate
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these findings with respect to other reports, comparing neurodevelopmental outcome studies is fraught with significant
challenges. Cohort inclusion criteria including gestational
age, birth years, and other factors may differ, as may assessment instruments or versions of instruments. Similarly, clinical and sociodemographic factors and definitions of NDI vary
by study, further confounding comparisons.27
Such factors may result in substantial differences in
reported rates of NDI and severe NDI. Nevertheless, these
findings are similar to those reported by Synnes et al.7 Their
report from a more mature cohort (up to 29 weeks’ gestational age) reported slightly lower overall NDI and severe NDI
rates; however, rates of severe NDI at 24 weeks (about 30%),
25 weeks (about 20%), and 26 weeks (about 18%) were consistent with our findings. The EPICure 2 study followed up
children born before 26 weeks’ gestational age in the United
Kingdom in 2006 to age 2.5 to 3 years and reported a 19%
severe NDI rate but used a definition restricted to developmental quotients more than 3 SDs below the mean.10 The
Swedish EXPRESS study followed up children born before 27
weeks’ gestational age in 2004-2007, reporting that 58% had
some level of disability at 30 months’ corrected age. Only 11%
were reported to have severe disability, but the definition
used included Bayley-III composite cognitive, language, or
motor scores more than 3 SDs below the mean.28 Kono et al4
presented 3-year outcomes from the Neonatal Research Network of Japan for children born before 25 weeks’ gestational
age in 2008-2012. They reported an NDI rate of 38.1% among
those with neurodevelopmental follow-up using a developmental test standardized for Japanese children, but the
follow-up rate was only 60.6%.
Composite end points such as NDI and disability at toddler age are commonly used outcomes for clinical studies in
neonatology. Contemporary early neurodevelopmental outcome data are also used in parent counseling at the time of
threatened extremely preterm delivery and in the neonatal
intensive care unit (NICU) during discussions regarding longterm transitions. However, these composite outcomes may
be confusing to parents, conflate multiple end points of
varying value to parents, and frame discussions in a negative
way.12,29,30 Parents may be more interested in understanding
“real-life” outcomes to develop a personalized and functional picture for the future, yet these outcomes are inconsistently reported. Information regarding post-NICU rehospitalizations, feeding, equipment, and medication needs may
inform both complex home care preparations and healthrelated quality-of-life considerations and thus may be more
meaningful for families.14,31 Hospitalization after NICU dis-
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charge was common, with nearly half of all children being
rehospitalized at least once by 22 to 26 months, consistent
with previous reports.32-34 Profound functional neurosensory impairments were rare for the cohort overall, including
blindness and severe functional hearing impairment. The
rate of severe cerebral palsy was also low.
The overall survival for infants of 22-28 weeks’ gestational age has continued to increase since 2008-2012,1 even
though more infants born at 22 weeks were being actively
treated in this more recent cohort. The survival of infants liveborn at 22 weeks is similar to more recently reported survival
among infants born at 22 weeks from the Vermont Oxford
Network.35 Higher survival for infants born at 22 weeks has
been reported from Japan4 and Sweden.5
Strengths of this study include the large number of
infants with high follow-up rates and rigorous prospective
data collection including neurodevelopmental assessments by certified evaluators. This study reports survival
both for all live-born infants and for only those actively
treated. In addition, it reports often overlooked 2-year neurodevelopmental and functional outcomes of importance
to families.29,30

Limitations
This study has several limitations. First, the Neonatal
Research Network cohort is hospital-based rather than
population-based. Although large and diverse, both in terms
of geography and sociodemographics, this cohort does not
represent the entire US preterm population but, rather, a
selected population from academic medical centers. Second,
the 2-year end points presented provide only a limited window into the future. Individual prediction of later childhood
outcomes at 2 years has limitations.36 The complexity of
developmental and cognitive milestones increases throughout childhood and adolescence, and engagement of both parents and children in health-related quality-of-life and other
outcome assessments should continue through later childhood and into adulthood.14,31,37

Conclusions
Among extremely preterm infants born in 2013-2018 and
treated at 19 US academic medical centers, 78.3% survived to
discharge, a significantly higher rate than for infants born in
2008-2012. Among infants born at less than 27 weeks’ gestational age, rehospitalization and severe neurodevelopmental
impairment were common at 2 years.
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